- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01569763
Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation
March 20, 2018 updated by: Minerva Surgical, Inc.
Minerva Pivotal Study
The primary objective of this study is to evaluate the safety and effectiveness of the Aurora Endometrial Ablation System as compared to hysteroscopic rollerball endometrial ablation in reducing menstrual blood loss at 12 months post-treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Menorrhagia is defined as menstrual bleeding in the ovulatory woman exceeding 80 ml per month.
Approximately 20-25% of healthy premenopausal women have abnormal uterine bleeding.
Menorrhagia can have a negative impact on a woman's lifestyle and self-perception, often leading her to seek definitive treatment.
Pharmacologic treatment for menorrhagia is not always successful, and dilatation and curettage typically provides relief for only a few menstrual cycles.
Traditionally hysterectomy has been the definitive treatment for menorrhagia.
This clinical study evaluates the safety and effectiveness of the Aurora Endometrial Ablation System to provide a therapeutic treatment for menorrhagia due to benign causes by ablating the endometrial lining of the uterus in pre-menopausal women for whom childbearing is complete.
Subjects who are randomized to the control group will receive hysteroscopic rollerball/resection ablation.
Subjects randomized to the test arm will be treated with the Aurora Endometrial Ablation System.
Study Type
Interventional
Enrollment (Actual)
153
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Quebec, Canada, G1W 2J5
- La Cite Medicale
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N3Z5
- McMaster University/Hamilton Health Sciences
-
-
Quebec
-
Ville Lassalle, Quebec, Canada, H8P 1C1
- Hôpital Lasalle
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4S 6X3
- Regina Qu'Appelle Health Region
-
-
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, Mexico, 64460
- Hospital Universitario, UANL
-
-
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- New Horizons Women's Care
-
Phoenix, Arizona, United States, 85015
- Women's Health Research
-
-
Indiana
-
Newburgh, Indiana, United States, 47630
- Basinski, LLC
-
-
Kansas
-
Wichita, Kansas, United States, 67226
- Cypress Medical Research Center, LLC
-
-
Minnesota
-
Edina, Minnesota, United States, 55435
- Minnesota Gynecology and Surgery
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Mercy Clinic Minimally Invasive Gynecology
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Women's Care PC
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Baylor Research Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Refractory menorrhagia with no definable organic cause
- Female subject from (and including) age 25 to 50 years
- Uterine sound measurement of no greater than10.0cm (external os to internal fundus) and a minimum uterine cavity length of 4.0cm
A minimum menstrual blood loss of ≥ 160 ml for two baseline cycles within three months prior to treatment as measured by alkaline hematin extraction; OR,
- A minimum menstrual blood loss of ≥ 160 ml for one baseline cycle for women who either
- had at least 3 prior months documented failed medical therapy; or
- had a contraindication to medical therapy
- Premenopausal at enrollment as determined by FSH measurement ≤ 40 IU/L
- Not pregnant and no desire to conceive at any time
- Subject agrees to use a reliable form of contraception up to the 12-month follow-up visit. If a hormonal birth control method is used for contraception, the subject must have been on said method for ≥ 3 months prior to enrollment and agrees to remain on the same hormonal regimen through the initial 12-month follow-up
- Able to provide written informed consent using a form that has been approved by the reviewing IRB/EC
- Subject agrees to follow-up exams and data collection requirements
- Subject who is literate or demonstrates an understanding on how to collect menstrual blood loss products for the alkaline hematin method of analysis
Exclusion Criteria:
- Pregnancy or subject with a desire to conceive
- Endometrial hyperplasia as confirmed by histology
- Presence of active endometritis
- Active pelvic inflammatory disease
- Active sexually transmitted disease (STD)
- Presence of bacteremia, sepsis, or other active systemic infection
- Active infection of the genitals, vagina, cervix, uterus or urinary tract at the time of the procedure
- Known/suspected abdominal pelvic or gynecological malignancy within the past 5 years
- Known clotting defects or bleeding disorders
- Untreated/unevaluated cervical dysplasia, except CIN I
- Prior uterine surgery (except low segment cesarean section) that interrupts the integrity of the uterine wall (e.g., transmural myomectomy or classical cesarean section)
- Previous endometrial ablation procedure
- Presence of an implantable (intrauterine) contraceptive device (e.g. Essure™ or Adiana™)
- Currently on medications that could thin the myometrial muscle, such as long-term steroid use (except inhaler or nasal therapy for asthma)
- Currently on anticoagulants
- Abnormal or obstructed cavity as confirmed by hysteroscopy, SIS or vaginal ultrasound
- Presence of an intrauterine device (IUD) which the Subject is unwilling to have removed at the time of the operative visit
- Subject currently on hormonal birth control therapy (including the Mirena device) for <3 months prior to enrollment
- Subject who is unwilling to use birth control post-ablation whether non-hormonal birth control or the same hormonal birth control therapy as before the procedure
- Subject who is within 6-weeks post partum
- Any subject who is currently participating or considers future participation in a research study of an investigational drug or device during the course of this investigational study
- Any general health condition which, in the opinion of the Investigator, could represent an increased risk for the subject
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: hysteroscopic rollerball resection/ablation
|
Hysteroscopic rollerball resection/ablation
|
Experimental: Aurora Endometrial Ablation
|
Endometrial Ablation using the Aurora Endometrial Ablation system
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of Menstrual Bleeding to Normal or Below Normal at 12 Months
Time Frame: 12 months
|
Clinical success was defined as a reduction in menstrual bleeding volume to ≤ 80 ml as measured by the alkaline hematin method (AH).
Clinical success was not achieved if: (1) at one year post-treatment menstrual blood loss is greater than 80ml, as measured by AH; (2) an acute failure occurred (e.g., aborted procedure, etc.); or (3) the subject required additional therapy to control menorrhagia.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure Time
Time Frame: < 1 hour
|
Procedure time is defined as the time from device insertion to time of device removal.
|
< 1 hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Eugene Skalnyi, MD, Minerva Surgical, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (Actual)
January 1, 2015
Study Completion (Actual)
March 2, 2018
Study Registration Dates
First Submitted
March 30, 2012
First Submitted That Met QC Criteria
March 30, 2012
First Posted (Estimate)
April 3, 2012
Study Record Updates
Last Update Posted (Actual)
April 18, 2018
Last Update Submitted That Met QC Criteria
March 20, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIP0005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menorrhagia
-
BayerCompletedIdiopathic MenorrhagiaCroatia, Saudi Arabia, Bulgaria, Jordan, Romania, Russian Federation, Turkey, United Arab Emirates, Kuwait, India, Pakistan, Serbia, Sri Lanka
-
BayerCompletedIdiopathic MenorrhagiaCroatia, South Africa, Colombia, Czech Republic, Jordan, Lebanon, Macedonia, The Former Yugoslav Republic of, Moldova, Republic of, Romania, Ukraine, Venezuela, Bosnia and Herzegovina, Syrian Arab Republic, Albania
-
Legacy Health SystemUnknownMenopause | Climacteric; Menorrhagia, MenopausalUnited States
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesHungary
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesMexico
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesCanada
-
Faculty of Medicine, SousseCentre Hôpital Universitaire Farhat HachedCompletedMetrorrhagia | Hysterectomy | Heavy Menstrual Bleeding | Abnormal Uterine Bleeding | Menorrhagia; PostmenopausalTunisia
-
University of Sao PauloRecruitingCardiovascular Diseases | Arterial Hypertension | Postmenopausal; MenorrhagiaBrazil
-
BayerCompletedMenorrhagia, DysmenorrheaJapan
-
University of Sao PauloRecruitingMotor Activity | Physical Inactivity | Postmenopausal; MenorrhagiaBrazil
Clinical Trials on Rollerball Ablation/Resection
-
Medtronic - MITGCompletedLung CancerUnited States, Germany
-
Chinese PLA General HospitalActive, not recruitingPapillary Thyroid CarcinomaChina
-
Sun Yat-sen UniversityRecruitingSurgery | Recurrent Nasopharyngeal CarcinomaChina
-
Interscope, Inc.RecruitingBarrett's Esophagus With DysplasiaUnited States, Sweden, United Kingdom
-
Amsterdam UMC, location VUmcMedtronic - MITGRecruitingSurgery | Liver Metastases | ColoRectal Cancer | Liver Metastasis Colon CancerNetherlands
-
Mostafa HusseinAssiut UniversityCompletedDysfunction Uterine BleedingEgypt
-
Linkoeping UniversityKarolinska University Hospital; Lund University; Oslo University Hospital; University... and other collaboratorsNot yet recruiting
-
Valley Health SystemCompleted
-
Karolinska InstitutetCompletedNeoplasm MetastasisNetherlands, Sweden, Switzerland
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Second Affiliated Hospital...RecruitingSecondary Malignant Neoplasm of LiverChina